Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ACH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAccendra completes + debt restructuring with new 9% and 9.75% secured notes
Filed June 15, 2026 · Period ending June 9, 2026 · ~1 min read
Key Changes
-
high
Issued two new series of secured notes: First Lien at 9.000% and Second Lien at 9.750%, both paying semi-annually starting December 2026. Notes secured by substantially all company assets in exchange for existing 2029 notes plus new money.
Item 1.01 verify on EDGAR → -
high
Established new $300M revolving credit facility due 2030, replacing prior facility. Must maintain leverage ratio below 5.50x through 2027, tightening to 4.50x thereafter, and interest coverage above 2.00x. Covenant violations could trigger default.
Item 1.01 verify on EDGAR → -
high
Management warned that failure to complete the exchange offers could materially adversely affect the company's financial condition, indicating the restructuring is critical to financial health.
Item 8.01 verify on EDGAR → -
medium
Obtained lender consent to waive mandatory prepayment on up to $400M in asset sale proceeds, allowing company to retain divestiture cash rather than paying down term loans. Provides greater financial flexibility.
Item 1.01 verify on EDGAR → -
medium
New notes include change of control provisions requiring company to offer repurchase at 101% of principal plus accrued interest if ownership changes occur, protecting noteholders with exit option at premium.
Item 1.01 verify on EDGAR →
Summary
Accendra Health completed a comprehensive debt restructuring on June 15, 2026, issuing two new series of secured notes at 9.000% and 9.750% interest rates while establishing a new $300 million revolving credit facility. The transaction exchanges existing 2029 notes for new securities secured by substantially all company assets, with the higher-rate Second Lien notes subordinated to First Lien debt.
Management explicitly warned that failure to complete these offers could materially harm the company's financial condition, signaling the restructuring's importance to ongoing operations. Retail investors should note the tightening financial constraints: the new credit facility imposes leverage covenants requiring ratios below 5.50x through 2027, then 4.50x thereafter, with interest coverage maintained above 2.00x.
Violating these covenants could trigger default and accelerate debt repayment. The company did secure flexibility by obtaining waivers on $400 million in asset sale prepayments, suggesting potential divestitures ahead. Watch for quarterly earnings reports to monitor compliance with the new leverage and coverage covenants, as any breach could force additional restructuring or asset sales at unfavorable terms.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Accendra completed debt restructuring: issued new secured notes, amended credit facilities, and exchanged existing notes.
Added in current filing · verify on EDGAR →
Pursuant to the Fourth Amendment, a new $300.0 million revolving credit facility (with the last $50 million available only in connection with mergers and acquisitions, and subject to compliance with certain leverage ratios) (the “New Revolving Credit Facility”) due in 2030, subject to a springing maturity of 91 days inside intervening maturities of certain indebtedness in excess of $25.0 million in aggregate principal amount, was established and the existing revolving credit facility thereunder was cancelled.
The company established a new $300 million revolving credit facility maturing in 2030, replacing the prior facility. The last $50 million is restricted to merger and acquisition use. The facility includes a springing maturity provision that accelerates repayment to 91 days before other debt maturities exceeding $25 million. The company is also restricted from borrowing if it would result in more than $50 million of unrestricted cash on the balance sheet.
Event · Item 8.01 — Other Events
Company announced early results of Exchange Offers and Consent Solicitations via press release on June 10, 2026.
Added in current filing · verify on EDGAR →
On June 10, 2026, the Company issued a press release announcing the early results of the Exchange Offers and Consent Solicitations, which is filed hereto as Exhibit 99.1 and incorporated by reference herein.
The company disclosed early results of ongoing Exchange Offers and Consent Solicitations through a press release. The actual results and terms are contained in the attached press release exhibit, not detailed in the 8-K body itself.
Added in current filing · verify on EDGAR →
The New Notes and the related guarantees to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and unless so registered, New Notes and the related guarantees may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.
The company disclosed that the New Notes being offered in the exchange have not been registered under the Securities Act and will be issued under an exemption. This is standard for exchange offers but limits the marketability and liquidity of the new securities.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 15, 2026 · How we verify